Several mTOR inhibitors have been approved by the United States Food and Drug Administration (US FDA) for a number of cancer types [14,15]; however, as single agents, these compounds have shown only limited efficacy in clinical trials, only slowing the growth of the tumors rather than being cytotoxic [16]. The gene discussed is MTOR; the disease is cancer.